Brief: JW (Cayman) Therapeutics Says Entered Into Collaboration Agreement With 2Seventy Bio
27/10/2022 01:50
Oct 27 (Reuters) - JW (Cayman) Therapeutics Co Ltd
2126.HK :
* ENTERED INTO COLLABORATION AGREEMENT WITH 2SEVENTY BIO
* DEAL FOR DEVELOPMENT & COMMERCIALIZATION IN GREATER CHINA
OF
CELL THERAPY PRODUCT
Source text for Eikon: ID:
Further company coverage: 2126.HK
Recent news on JW (Cayman) Therapeutics
See all newsChina's JW Therapeutics interim revenue rises 4.7% on Carteyva sales
China pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million